erlotinib — Medica
Renal Cell Carcinoma (non-clear cell histology, papillary or HLRCC-associated)
Initial criteria
- age ≥ 18 years
- Stage IV or relapsed renal cell carcinoma of non-clear cell histology
- advanced papillary disease including hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated renal cell carcinoma
- used in combination with bevacizumab
Approval duration
1 year